中国卫生标准管理
中國衛生標準管理
중국위생표준관리
China Health Standard Management
2015年
27期
108-110
,共3页
布地奈德福莫特罗%噻托溴铵%联合用药%慢性阻塞性肺疾病%慢性呼吸衰竭
佈地奈德福莫特囉%噻託溴銨%聯閤用藥%慢性阻塞性肺疾病%慢性呼吸衰竭
포지내덕복막특라%새탁추안%연합용약%만성조새성폐질병%만성호흡쇠갈
Budesonide/formoterol%Tiotropium%Combination therapy%Chronic obstructive pulmonary disease%Chronic respiratory failure
目的 观察布地奈德福莫特罗与噻托溴铵联合吸入对合并慢性呼吸衰竭的慢性阻塞性肺疾病(COPD)稳定期患者的疗效.方法 选取 2011 年1月~2013年12月于本院呼吸科门诊就诊的90例合并慢性呼吸衰竭的稳定期COPD患者,采用完全随机法分成 3 组(即布地奈德福莫特罗组、噻托溴铵组、布地奈德福莫特罗与噻托溴铵联合组),共治疗6个月.分别于治疗前和治疗后测定患者肺功能(FEV1%)、动脉血气分析,记录慢性阻塞性肺疾病评估测试量表评分及半年内急性加重次数.结果 布地奈德福莫特罗组和噻托溴铵组肺功能(FEV1%)、血气分析,慢性阻塞性肺疾病评估测试量表评分较治疗前改善(P<0.05),联合组各项指标改善优于其他两组(P<0.05).联合组急性加重次数较其余两组减少(P<0.05).结论 布地奈德福莫特罗及噻托溴铵联合吸入对合并慢性呼吸衰竭的COPD稳定期患者疗效肯定,优于单一药物治疗.
目的 觀察佈地奈德福莫特囉與噻託溴銨聯閤吸入對閤併慢性呼吸衰竭的慢性阻塞性肺疾病(COPD)穩定期患者的療效.方法 選取 2011 年1月~2013年12月于本院呼吸科門診就診的90例閤併慢性呼吸衰竭的穩定期COPD患者,採用完全隨機法分成 3 組(即佈地奈德福莫特囉組、噻託溴銨組、佈地奈德福莫特囉與噻託溴銨聯閤組),共治療6箇月.分彆于治療前和治療後測定患者肺功能(FEV1%)、動脈血氣分析,記錄慢性阻塞性肺疾病評估測試量錶評分及半年內急性加重次數.結果 佈地奈德福莫特囉組和噻託溴銨組肺功能(FEV1%)、血氣分析,慢性阻塞性肺疾病評估測試量錶評分較治療前改善(P<0.05),聯閤組各項指標改善優于其他兩組(P<0.05).聯閤組急性加重次數較其餘兩組減少(P<0.05).結論 佈地奈德福莫特囉及噻託溴銨聯閤吸入對閤併慢性呼吸衰竭的COPD穩定期患者療效肯定,優于單一藥物治療.
목적 관찰포지내덕복막특라여새탁추안연합흡입대합병만성호흡쇠갈적만성조새성폐질병(COPD)은정기환자적료효.방법 선취 2011 년1월~2013년12월우본원호흡과문진취진적90례합병만성호흡쇠갈적은정기COPD환자,채용완전수궤법분성 3 조(즉포지내덕복막특라조、새탁추안조、포지내덕복막특라여새탁추안연합조),공치료6개월.분별우치료전화치료후측정환자폐공능(FEV1%)、동맥혈기분석,기록만성조새성폐질병평고측시량표평분급반년내급성가중차수.결과 포지내덕복막특라조화새탁추안조폐공능(FEV1%)、혈기분석,만성조새성폐질병평고측시량표평분교치료전개선(P<0.05),연합조각항지표개선우우기타량조(P<0.05).연합조급성가중차수교기여량조감소(P<0.05).결론 포지내덕복막특라급새탁추안연합흡입대합병만성호흡쇠갈적COPD은정기환자료효긍정,우우단일약물치료.
Objective To evaluate the effects of the combination treatment of budesonide/formoterol and tiotropium in stable COPD patients with chronic respiratory failure.Methods 90 patients with stable COPD combined chronic respiratory failure were recruited from January 2011 to December 2013 in our hospital. The patients were randomly divided into three groups(Budesonide/formoterol group,Tiotropium group and combination group). Al patients had received treatment for 6 months.Before and after the treatment,lung function(FEV1%),blood gas analysis(PO2 and PCO2), chronic obstructive pulmonary disease assessment test(CAT) score were assessed. The number of exacerbations were also recorded during 6 months. ResultsLung function, blood gas analysis,and the CAT score were improved in al groups compared with baseline(P<0.05),especialy in the combination group(P<0.05). Compared with the Budesonide/formoterol group and the Tiotropium group,the combination therapy significantly decreased the incidence of exacerbations(P<0.05).Conclusion Budesonide/formoterol combined Tiotropium is effective for the treatment of stable COPD patients with chronic respiratory failure,which is better than a single drug treatment.
